This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
27,99 € / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
276,54 € per year
only 23,05 € per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kämpe, A. et al. Preprint at SSRN https://doi.org/10.2139/ssrn.4992987 (2024).
Uhlén, M. et al. Science 347, 1260419 (2015).
Government Offices of Sweden. Regerinskansliet https://go.nature.com/4hrlIaV (7 November 2024).
Fioretos, T. et al. Nat. Med. 28, 1980–1982 (2022).
Bergström, G. et al. J. Intern. Med. 278, 645–659 (2015).
Späth, F. et al. Int. J. Epidemiol. 16, dyaf004 (2024).
Brueffer, C. et al. EMBO Mol. Med. 12, e12118 (2020).
Nunes, L. et al. Nature 633, 137–146 (2024).
Tesi, B. et al. Lancet Reg. Health Eur. 39, 100881 (2024).
Stranneheim, H. et al. Genome Med. 13, 40 (2021).
Fröbert, O. et al. N. Engl. J. Med. 369, 1587–1597 (2013).
Acknowledgements
The authors thank Barncancerfonden, J. Vallon-Christersson, M. Friedman, U. Landegren and others in the precision medicine and multi-omics community in Sweden and abroad for invaluable discussions that have contributed to the ideas formulated here. The authors receive research and infrastructure funding from the Swedish Research Council, the Swedish Society for Medical Research, the Knut and Alice Wallenberg Foundation, Vinnova, Forskningsrådet i Sydöstra Sverige, Region Östergötland, the Swedish Cancer Society, the Swedish Brain Foundation, the Swedish Heart Lung Foundation, the Swedish Childhood Cancer Fund, Region Skåne, the European Research Council, Region Stockholm, the Sjöberg Foundation, Radiumhemmets forskningsfonder, SciLifeLab, National Institutes of Health, the Erling Persson Foundation, Uppsala University, the Mrs. Berta Kamprad Foundation and the Göran Gustafsson Foundation.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
T.F. is co-founder, board member and scientific advisor to Qlucore and Lead Biologics and co-founder and scientific advisor to Cantargia. P.F. is a paid member of advisory boards for Novo Nordisk, Sidra Health, Zoe and ABC Labs; has received research funding (paid to institution) from numerous pharmaceutical companies as part of the Innovative Medicines Initiative of the European Union; and is co-chair of the Precision Medicine in Diabetes Initiative and the US National Institute of Diabetes and Digestive and Kidney Diseases Working Group of Council on Heterogeneity in Diabetes. L.S. is co-founder and shareholder of SAGA Diagnostics and advisor to DoMore Diagnostics and has received honoraria from AstraZeneca. J.S. has conducted contract research (paid to institution) for Capitainer and Luminex and has received speaker/travel fees from Roche Diagnostics, Olink and Luminex. E.M. has received advisory board or lecture honoraria from ALK, AstraZeneca, Chiesi and Sanofi. J.S. has direct or indirect stock ownership in companies (Anagram kommunikation, Sence Research, Symptoms Europe and MinForskning) providing services to companies and authorities in the health sector, including Amgen, AstraZeneca, Bayer, Boehringer, Eli Lilly, Gilead, GSK, Göteborg University, Itrim, Ipsen, Janssen, Karolinska Institutet, LIF, Linköping University, Novo Nordisk, Parexel, Pfizer, Region Stockholm, Region Uppsala, Sanofi, STRAMA, Takeda, TLV, Uppsala University, Vifor Pharma and WeMind. B.V.G. has received speaker honoraria from AstraZeneca. T.S. is co-founder, shareholder and board member of Oncodia. R.R. has received honoraria from AbbVie, AstraZeneca, Illumina, Janssen, Lilly and Roche. A.L. has received speaker honoraria from Illumina and Pacific Biosciences. T.L. is a scientific advisor to and has equity in Variant Bio and has received speaker honoraria from Abbvie and Merck.
Rights and permissions
About this article
Cite this article
Kämpe, A., Gudmundsson, S., Walsh, C.P. et al. Precision Omics Initiative Sweden (PROMISE) will integrate research with healthcare. Nat Med 31, 1730–1732 (2025). https://doi.org/10.1038/s41591-025-03631-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-025-03631-9
